Tags

Type your tag names separated by a space and hit enter

Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria.
Afr J Med Med Sci. 1988 Dec; 17(4):195-200.AJ

Abstract

In Nigeria chloroquine remains the drug of choice for the treatment of falciparum malaria since chloroquine resistance is not yet a problem. Nevertheless, in view of the rapid spread of multi-resistant Plasmodium falciparum in Africa, it is desirable to test alternative drugs for efficacy and safety. To this end we undertook a comparative controlled trial of the new triple combination, mefloquine-sulphadoxine-pyrimethamine (MSP, Fansimef, Hoffman-La Roche, Switzerland) with chloroquine in a group of Nigerian children with symptomatic falciparum malaria. Our results showed that Fansimef was a rapidly acting blood schizontocide against the Nigerian strain of P. falciparum, and was well tolerated. In particular, sinus bradycardia, which was frequently observed with Fansimef in the trials conducted in Zambia, was not seen in any of the Nigerian patients.

Authors+Show Affiliations

Department of Pharmacology and Therapeutics, University of Ibadan, Nigeria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2854365

Citation

Fadeke Aderounmu, A, et al. "Comparison of the Susceptibility of Falciparum Malaria to Mefloquine-sulphadoxine-pyrimethamine and Chloroquine in Nigeria." African Journal of Medicine and Medical Sciences, vol. 17, no. 4, 1988, pp. 195-200.
Fadeke Aderounmu A, Salako LA, Laoye AJ, et al. Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria. Afr J Med Med Sci. 1988;17(4):195-200.
Fadeke Aderounmu, A., Salako, L. A., Laoye, A. J., Modupe Makinde, J., & Aina Adio, R. (1988). Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria. African Journal of Medicine and Medical Sciences, 17(4), 195-200.
Fadeke Aderounmu A, et al. Comparison of the Susceptibility of Falciparum Malaria to Mefloquine-sulphadoxine-pyrimethamine and Chloroquine in Nigeria. Afr J Med Med Sci. 1988;17(4):195-200. PubMed PMID: 2854365.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria. AU - Fadeke Aderounmu,A, AU - Salako,L A, AU - Laoye,A J, AU - Modupe Makinde,J, AU - Aina Adio,R, PY - 1988/12/1/pubmed PY - 1988/12/1/medline PY - 1988/12/1/entrez SP - 195 EP - 200 JF - African journal of medicine and medical sciences JO - Afr J Med Med Sci VL - 17 IS - 4 N2 - In Nigeria chloroquine remains the drug of choice for the treatment of falciparum malaria since chloroquine resistance is not yet a problem. Nevertheless, in view of the rapid spread of multi-resistant Plasmodium falciparum in Africa, it is desirable to test alternative drugs for efficacy and safety. To this end we undertook a comparative controlled trial of the new triple combination, mefloquine-sulphadoxine-pyrimethamine (MSP, Fansimef, Hoffman-La Roche, Switzerland) with chloroquine in a group of Nigerian children with symptomatic falciparum malaria. Our results showed that Fansimef was a rapidly acting blood schizontocide against the Nigerian strain of P. falciparum, and was well tolerated. In particular, sinus bradycardia, which was frequently observed with Fansimef in the trials conducted in Zambia, was not seen in any of the Nigerian patients. SN - 0309-3913 UR - https://www.unboundmedicine.com/medline/citation/2854365/Comparison_of_the_susceptibility_of_falciparum_malaria_to_mefloquine_sulphadoxine_pyrimethamine_and_chloroquine_in_Nigeria_ L2 - https://www.diseaseinfosearch.org/result/4415 DB - PRIME DP - Unbound Medicine ER -